Abstract
The Hsp90 chaperones play a key role in regulating the physiology of cells exposed to environmental stress and in maintaining the malignant phenotype in tumor cells. Agents that interfere with the function of the chaperone may thus be beneficial in the treatment of cancers. The ansamycins (geldanamycin and herbimycin) and the unrelated natural product radicicol were found to bind to the N-terminal pocket of Hsp90 and inhibit its function. However, translation of these compounds to the clinic was impeded by stability and hepatoxicity issues. 17AAG, a derivative of geldanamycin, was found to be less hepatotoxic and is currently undergoing Phase I clinical trial. Unfortunately, 17AAG is insoluble, difficult to formulate and it is not yet clear if therapeutically effective doses can be administered without escalating non-Hsp90 associated toxicities. Additionally, for reasons not yet completely understood, a subset of tumor cells are insensitive to the action of the drug. The development of novel agents that lack the drawbacks of the natural products is thus necessary. Here we present an overview of such efforts with focus on a new class of purine-scaffold Hsp90 inhibitors developed by rational design.
Keywords: Purine-Scaffold, Hsp90, phenotype, geldanamycin, herbimycin
Current Cancer Drug Targets
Title: Development of Purine-Scaffold Small Molecule Inhibitors of Hsp90
Volume: 3 Issue: 5
Author(s): Gabriela Chiosis, Brian Lucas, Henri Huezo, David Solit, Andrea Basso and Neal Rosen
Affiliation:
Keywords: Purine-Scaffold, Hsp90, phenotype, geldanamycin, herbimycin
Abstract: The Hsp90 chaperones play a key role in regulating the physiology of cells exposed to environmental stress and in maintaining the malignant phenotype in tumor cells. Agents that interfere with the function of the chaperone may thus be beneficial in the treatment of cancers. The ansamycins (geldanamycin and herbimycin) and the unrelated natural product radicicol were found to bind to the N-terminal pocket of Hsp90 and inhibit its function. However, translation of these compounds to the clinic was impeded by stability and hepatoxicity issues. 17AAG, a derivative of geldanamycin, was found to be less hepatotoxic and is currently undergoing Phase I clinical trial. Unfortunately, 17AAG is insoluble, difficult to formulate and it is not yet clear if therapeutically effective doses can be administered without escalating non-Hsp90 associated toxicities. Additionally, for reasons not yet completely understood, a subset of tumor cells are insensitive to the action of the drug. The development of novel agents that lack the drawbacks of the natural products is thus necessary. Here we present an overview of such efforts with focus on a new class of purine-scaffold Hsp90 inhibitors developed by rational design.
Export Options
About this article
Cite this article as:
Chiosis Gabriela, Lucas Brian, Huezo Henri, Solit David, Basso Andrea and Rosen Neal, Development of Purine-Scaffold Small Molecule Inhibitors of Hsp90, Current Cancer Drug Targets 2003; 3 (5) . https://dx.doi.org/10.2174/1568009033481778
DOI https://dx.doi.org/10.2174/1568009033481778 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Microbial Sensors Based on Nanostructures
Recent Patents on Nanomedicine A Review on Anti-Cancer Activity of Some of the Oil-Soluble Organosulphur Compounds Against Colon Cancer
Current Traditional Medicine Bioactivities of Rubidium Chloride-Poly (4-Vinylpyridine) Composite Fabricated Via Sol Gel Technique
Current Pharmaceutical Analysis Synthesis of Daumone Derivatives and their Antiangiogenic Activities on Chorioallantoic Membrane
Medicinal Chemistry An Improved Synthesis of m-Hydroxymexiletine, a Potent Mexiletine Metabolite
Drug Metabolism Letters Efficacy and Cardiovascular Safety of Thiazolidinediones
Current Drug Safety Bacterial Protein Toxins: Current and Potential Clinical Use
Current Medicinal Chemistry Synthesis, DNA Binding, Docking and Photoclevage Studies of Novel Benzo[b][1,8]naphthyridines
Medicinal Chemistry Use of High-Throughput Trypsin Digestion in Proteomic Studies
Current Proteomics Mechanisms and Treatment of Neuropathic Pain
Central Nervous System Agents in Medicinal Chemistry High-Throughput Screening by Nuclear Magnetic Resonance (HTS by NMR) for the Identification of PPIs Antagonists
Current Topics in Medicinal Chemistry Thermodynamics and information Physics Offer New Opportunities in Cancer Therapy
Current Cancer Therapy Reviews Interactions of Metal Ions with DNA, Its Constituents and Derivatives, which may be Relevant for Anticancer Research
Current Topics in Medicinal Chemistry Newly Recognized Receptors for Vitamin D Metabolites
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Microsome Biocolloids for Rapid Drug Metabolism and in hibition Assessment by LC-MS
Drug Metabolism Letters Advancement of Targeted Ultrasound Contrast Agents and their Applications in Molecular Imaging and Targeted Therapy
Current Pharmaceutical Design Monitoring Intracellular Proteins Using Fluorescence Techniques: From Protein Synthesis and Localization to Activity
Current Protein & Peptide Science Cell Microencapsulation Implants into the Central Nervous System
Recent Patents on Nanomedicine Current Synthetic Approaches to Peptide and Peptidomimetic Cyclization
Current Organic Chemistry Targeting the RAS Signaling Pathway in Malignant Hematologic Diseases
Current Drug Targets